GlobeNewswire by notified

Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipėdos nafta

Share

Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipėdos nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Exraordinary General Meeting of Shareholders of the Company will be held on 20 October 2022 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor).

Agenda of the meeting:

  1. Approval of amendment of Remuneration Policy of AB Klaipėdos nafta.

The shareholders will be registered from 12:00 a.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under the procedure prescribed by the laws).

A shareholder or his proxy shall have the right to vote in writing in advance by filling in a general ballot paper. At the request of the shareholder, the Company shall send a general ballot paper to the shareholder by registered mail free of charge at least 10 days before the meeting. The filled-in general ballot paper and the document attesting the voting right shall be submitted to the Company no later than until the meeting, sending by registered mail or providing them at the address of the registered office of the Company indicated in the notice.

The shareholders who hold shares carrying at least 1/20 of all the votes may propose additions to the agenda of the general meeting of shareholders by submitting with every proposed additional item of the agenda a draft resolution of the general meeting of shareholders or, when no resolution is required, an explanation. Proposals on addition to the agenda shall be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and s.granickiene@kn.lt . The agenda shall be supplemented if the proposal is received no later than 14 days before the Extraordinary General Meeting of Shareholders. If the agenda of the general meeting of shareholders is supplemented, the Company shall notify on the additions no later than 10 days before the meeting in the same ways as in the case of convocation of the meeting.

The shareholders, who hold shares carrying at least 1/20 of all the votes, at any time before the general meeting of shareholders or during the meeting, may propose new draft resolutions on items which are or will be included in the agenda of the meeting. The proposals may be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and s.granickiene@kn.lt.

The shareholders shall have the right to submit to the Company in advance questions relating to the items on the agenda of the meeting. The shareholders may submit their written questions to the Company on business days or send by registered mail at the address of the registered office of the Company indicated in the notice no later than 3 business days before the meeting. The Company will reply to the questions by e-mail or in writing before the meeting, except the questions which are related to the Company’s commercial (industrial) secret, confidential information or which have been submitted later than 3 business days before the meeting.

The Company does not provide the possibility of participating and voting at the meeting by means of electronic communications.

The shareholder shall have the right to authorize through electronic communications means another person (natural or legal) to participate and vote in the meeting on behalf of the shareholder. No notarization of such authorization is required. The shareholder must confirm the proxy issued through electronic communications means by an electronic signature developed by a secure signature-creation device and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder shall inform the Company on the proxy issued through electronic communications means to the following e-mails: info@kn.lt and s.granickiene@kn.lt no later than until the last business day before the meeting at 1:00 p.m. The proxy and the notice must be issued in writing. The proxy and the notice to the Company shall be signed with the electronic signature but not the letter sent by e-mail. By submitting the notice to the Company, the shareholder shall include the internet address from which it would be possible to download software free of charge to verify the shareholder’s electronic signature.

The record date of the meeting shall be 13 October 2022 (only those persons who will be shareholders of the Company at the close of the record date of the general meeting of shareholders or their authorized persons, or persons with whom an agreement on assignment of the voting right has been executed, may participate and vote at the general meeting of shareholders).

The shareholders of the Company may familiarise with the draft resolution of the meeting and the form of the general ballot paper under the procedure prescribed by the laws in the registered office of the Company at Buriu str. 19, Klaipeda (tel.: 8 46 391636), or on the Company’s website at http://www.kn.lt/. The following information and documents shall be provided on the abovementioned internet website of the Company:

- The notification on convocation of the meeting;

- Total number of the Company’s shares and the number of shares with voting rights on the convening day of the meeting.


Enclosed:

  1. Draft decision;
  2. Ballot paper;
  3. Remuneration policy.


Mindaugas Kvekšas, Chief Financial Officer, +370 46 391 772


Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

HMS Networks AB (publ) acquires Control Specialists Ltd9.12.2022 13:50:56 CET | Press release

HMS Industrial Networks Ltd, a wholly owned subsidiary of HMS Networks AB (publ), has today acquired all shares in Control Specialists Ltd, located in Manchester, United Kingdom. Control Specialists is a key partner to Procentec – HMS’ offering in monitoring and diagnostics of industrial networks. They deliver certifications and certified trainings related to industrial networks in the United Kingdom. Control Specialists is expected to realize a turnover of 0.5 MGBP in 2022 and will be integrated into HMS Industrial Networks Ltd during 2023 to further strengthen the Procentec training offering. The acquisition will have limited impact on HMS’s sales and earnings per share in 2022. For more information, please contact: Staffan Dahlström, CEO HMS Networks AB, +46 (0)35 17 29 01 Joakim Nideborn, CFO HMS Networks AB, +46 (0)35 710 6983 HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and m

HMS Networks AB (publ) förvärvar Control Specialists Ltd9.12.2022 13:50:56 CET | Pressemelding

HMS Industrial Networks Ltd, ett helägt dotterbolag till HMS Networks AB (publ), har idag förvärvat samtliga aktier i Control Specialists Ltd, beläget i Manchester, Storbritannien. Control Specialists är en viktig partner till Procentec – HMS erbjudande inom monitorering och diagnostik av industriella nätverk. De levererar certifieringar och certifieringsutbildningar relaterade till industriella nätverk i Storbritannien. Control Specialists förväntas omsätta 0,5 MGBP 2022 och kommer att integreras i HMS Industrial Networks Ltd under 2023 för att ytterligare stärka Procentecs utbildningserbjudande. Förvärvet kommer att ha en begränsad inverkan på HMS resultat per aktie 2022. För mer information, vänligen kontakta: CEO Staffan Dahlström, telefon: 035-17 29 01 CFO Joakim Nideborn, telefon: 035-71 06 983 HMS Networks AB (publ) är en marknadsledande leverantör av lösningar inom industriell informations- och kommunikationsteknologi (Industrial ICT). HMS utvecklar och tillverkar produkter und

Notice to attend the Extraordinary General Meeting in Auriant Mining AB (publ.)9.12.2022 13:41:36 CET | Press release

The shareholders in Auriant Mining AB (publ.) (”Company” or “Auriant Mining”), 556659-4833, are hereby summoned to the Extraordinary General Meeting on Wednesday, 28 December 2022. The Board of Directors has decided that the Extraordinary General Meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties in accordance with temporary legal rules. There will be no opportunity for shareholders to attend the general meeting in person or by proxy. Auriant Mining welcomes all shareholders to exercise their voting rights at this Extraordinary General Meeting through advance voting on the basis of temporary statutory rules, according to the procedure set out below. Information on the resolutions passed at the Extraordinary General Meeting will be published on 28 December 2022, as soon as the result of the voting has been finally confirmed. In the advance voting form, the shareholders may request that a resolution on one or several of

Kallelse till extra bolagsstämma i Auriant Mining AB (publ.)9.12.2022 13:41:36 CET | Pressemelding

Aktieägarna i Auriant Mining AB (publ.) (”Bolaget” eller ”Auriant Mining”), 556659-4833, kallas härmed till extra bolagsstämma onsdagen den 28 december 2022. Styrelsen har beslutat att den extra bolagsstämman ska genomföras enbart genom förhandsröstning, utan fysisk närvaro av aktieägare, ombud och utomstående i enlighet med tillfälliga lagregler. Det kommer inte att finnas någon möjlighet för aktieägare att närvara vid stämman personligen eller genom ombud. Auriant Mining välkomnar alla aktieägare att utnyttja sin rösträtt vid denna extra bolagsstämma genom förhandsröstning med stöd av tillfälliga lagregler, i den ordning som anges nedan. Information om de vid extra bolagsstämman fattade besluten offentliggörs den 28 december 2022 så snart utfallet av röstningen är slutligt sammanställt. Aktieägarna kan i förhandsröstningsformuläret begära att beslut i något eller några av ärendena på den föreslagna dagordningen nedan ska anstå till en s.k. fortsatt bolagsstämma, som inte får vara en

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)9.12.2022 13:30:00 CET | Press release

CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. ACTEMRA® is indicated for several indications, including moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and systemic juvenile idiopathic arthritis. “The FDA filing is supported by Phase 3 data from a comparative clinical trial demonstrating equivalent efficacy and a comparable safety and immunogenicity profile to the reference product,” said Ian Henshaw, Head of Global Biosimilars at Biogen. “We look forward to working with regulators to bring this potential treatment option for people with immune mediated inflammatory diseases.” As previously reported, positive Phase 32 data for BIIB800 up to week 24 w